IL-21 impairs pro-inflammatory activity of M1-like macrophages exerting anti-inflammatory effects on rheumatoid arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Huang Q, Ma Y, Adebayo A, et al. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 2007;56(7):2192–2201.
   PubMedGoogle Scholar
• Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther. 2007;9(6):224.
   PubMed Web of Science ®Google Scholar
• Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485.
   PubMed Web of Science ®Google Scholar
• Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012;14(5):445–454.
   PubMed Web of Science ®Google Scholar
• Ambarus CA, Noordenbos T, de Hair MJ, et al. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res Ther. 2012;14(2):R74.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57–63.
   PubMed Web of Science ®Google Scholar
• Marijnissen RJ, Roeleveld DM, Young D, et al. Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis. Arthritis Rheumatol. 2014;66(4):886–895.
   PubMedGoogle Scholar
• Pesce J, Kaviratne M, Ramalingam TR, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest. 2006;116(7):2044–2055.
   PubMed Web of Science ®Google Scholar
• Deenick EK, Tangye SG. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol. 2007;85(7):503–505.
   PubMedGoogle Scholar
• Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542(7639):110–114.
   PubMed Web of Science ®Google Scholar
• Liu R, Wu Q, Su D, et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther. 2012;14(6):R255.
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002;16(4):559–569.
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014;13(5):379–395.
   PubMed Web of Science ®Google Scholar
• Strengell M, Lehtonen A, Matikainen S, et al. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol. 2006;79(6):1279–1285.
   PubMedGoogle Scholar
• Vallieres F, Girard D. IL-21 enhances phagocytosis in mononuclear phagocyte cells: identification of spleen tyrosine kinase as a novel molecular target of IL-21. J Immunol. 2013;190(6):2904–2912.
   PubMedGoogle Scholar
• Wan CK, Oh J, Li P, et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity. 2013;38(3):514–527.
   PubMedGoogle Scholar
• Dinesh P, Rasool M. Multifaceted role of IL-21 in rheumatoid arthritis: Current understanding and future perspectives. J Cell Physiol. 2018;233(5):3918–3928.
   PubMedGoogle Scholar
• Brandt K, Singh PB, Bulfone-Paus S, et al. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 2007;18(3-4):223–232.
   PubMedGoogle Scholar
• Gottenberg JE, Dayer JM, Lukas C, et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(7):1243–1248.
   PubMed Web of Science ®Google Scholar
• Xing R, Sun L, Wu D, et al. Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37(1):75–80.
   PubMedGoogle Scholar
• Chanput W, Mes JJ, Savelkoul HF, et al. Characterization of polarized THP-1 macrophages and polarizing ability of LPS and food compounds. Food Funct. 2013;4(2):266–276.
   PubMed Web of Science ®Google Scholar
• Jian L, Sun L, Li C, et al. Interleukin-21 enhances toll-like receptor 2/4-mediated cytokine production via phosphorylation in the STAT3, akt and p38 MAPK signalling pathways in human monocytic THP-1 cells. Scand J Immunol. 2019;89:e12761.
   PubMed Web of Science ®Google Scholar
• Jungel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 2004;50(5):1468–1476.
   PubMedGoogle Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555.
   PubMed Web of Science ®Google Scholar
• Niu X, He D, Zhang X, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol. 2010;71(4):334–341.
   PubMedGoogle Scholar
• Rasmussen TK, Andersen T, Hvid M, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 2010;37(10):2014–2020.
   PubMed Web of Science ®Google Scholar
• Sglunda O, Mann HF, Hulejova H, et al. Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. Physiol Res. 2014;63:475–481.
   PubMed Web of Science ®Google Scholar
• Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56(4):1152–1163.
   PubMedGoogle Scholar
• Ignatenko S, Skrumsager BK, Mouritzen U. Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial. CP. 2016;54(04):243–252.
   Google Scholar
• Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(6):834–838.
   PubMed Web of Science ®Google Scholar
• Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9–17.
   PubMed Web of Science ®Google Scholar
• Ruckert R, Bulfone-Paus S, Brandt K. Interleukin-21 stimulates antigen uptake, protease activity, survival and induction of CD4+ T cell proliferation by murine macrophages. Clin Exp Immunol. 2008;151(3):487–495.
   PubMedGoogle Scholar
• Vallieres F, Girard D. Mechanism involved in interleukin-21-induced phagocytosis in human monocytes and macrophages. Clin Exp Immunol. 2017;187(2):294–303.
   PubMedGoogle Scholar
• Vallieres F, Durocher I, Girard D. Biological activities of interleukin (IL)-21 in human monocytes and macrophages. Cell Immunol. 2019;337:62–70.
   PubMedGoogle Scholar
• Fuqua CF, Akomeah R, Price JO, et al. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine. 2008;44(1):101–107.
   PubMedGoogle Scholar
• Li SN, Wang W, Fu SP, et al. IL-21 modulates release of proinflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Mediators Inflamm. 2013;2013:548073.
   PubMedGoogle Scholar
• Kwok SK, Cho ML, Park MK, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum. 2012;64(3):740–751.
   PubMedGoogle Scholar
• Xing R, Yang L, Jin Y, et al. Interleukin-21 induces proliferation and proinflammatory cytokine profile of fibroblast-like synoviocytes of patients with rheumatoid arthritis. Scand J Immunol. 2016;83(1):64–71.
   PubMedGoogle Scholar
• Xing R, Zhang Y, Li C, et al. Interleukin-21 promotes osteoclastogenesis in RAW264.7 cells through the PI3K/AKT signaling pathway independently of RANKL. Int J Mol Med. 2016;38(4):1125–1134.
   PubMed Web of Science ®Google Scholar
• Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17(6):349–362.
   PubMed Web of Science ®Google Scholar
• Lacey DC, Achuthan A, Fleetwood AJ, et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188(11):5752–5765.
   PubMed Web of Science ®Google Scholar
• Soler Palacios B, Estrada-Capetillo L, Izquierdo E, et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J Pathol. 2015;235(3):515–526.
   PubMed Web of Science ®Google Scholar